34 results about "Equine herpesvirus" patented technology

A vaccine for the selective immunization of horses against EHV4 and/or EHV1 is provided comprising at least one of (i) EHV4 virus wherein a portion of the gG gene of the EHV4 virus that elicits a type-specific response to EHV4 has been deleted and (ii) EHV1 virus wherein a portion of the gG gene of the EHV1 virus that elicits a type-specific response to EHV1 has been deleted. Antibodies which specifically bind to a epitopes of EHV4 gG or EHV1 also are provided.

The invention discloses an application of polycyclic polyketides in preparation of an anti-HV (herpes virus) drug. It is found that the polyketides can inhibit diseases caused by infection of four HVs including HSV-1 (herpes simplex virus-1), HSV-2 (herpes simplex virus-2), VZV (varicella zoster virus) and CMV (cytomegalo virus). The compounds show equivalent activity but have different acting mechanisms as compared with commercial drugs such as acyclovir and can overcome drug resistance of existing commercial drugs. Therefore, the compounds have good application prospects in treatment of related diseases caused by infection of HVs including HSV-1, HSV-2, VZV and CMV.

The present invention relates to novel Equine herpesvirus (EHV) mutants comprising one or more deletions, substitutions, or insertions in the endogenous promoter region of an essential viral gene, preferably the immediate early gene of EHV. The EHV mutants are stable and have reduced virulence, which makes them very suitable for use in a live vaccine. The invention furthermore relates to live vaccines comprising said EHV mutants, to DNA sequences and vectors harbouring a mutated EHV sequence, to host cells transfected with said DNA or vectors. The invention also relates to a method of attenuating EHV in general, and EHV-1 in particular.

The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.

The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.

The invention discloses Lamp (loop-mediated isothermal amplification) detection primers and a Lamp detection method for discrimination of equine herpesvirus type 1/4 and application thereof, belonging to the field of molecular biological diagnosis methods for animal virosis. A corresponding detection primer group is designed according to the gB gene sequence of equine herpesvirus by using Lamp technology and comprises outer primers FIP and BIP and inner primers F3 and B3, and the Lamp detection method for typing equine herpesvirus type 1 and equine herpesvirus type 4 is invented with the detection primer group as the detection primers. According to the invention, equine herpesvirus infection and typing and other functions at the level of DNA can be realized by carrying out extraction of total DNA and Lamp amplification on equine nose swab, equine brain tissue and lung tissue samples, and the characteristics of easiness, convenience, fastness, good specificity, easy determination of results and the like are obtained.

The invention provides a use of Tenovin-1 in preparing a drug. The drug is used for treating or preventing herpes virus infection. According to the embodiment of the invention, the Tenovin-1 can be effectively used for treating or preventing herpes virus infection. Detection on herpes viruses in different subtypes shows that, the Tenovin-1 has the activity of broad-spectrum anti-herpes viruses, ishigh in selection index, can be developed into a drug for treating herpes virus infection diseases and has a wide application prospect.

An object of the present invention is to find a protein expressed in a variety of cells and functioning as a receptor for herpesvirus and provide a preventive or remedy for herpesvirus infections capable of inhibiting binding of the receptor to herpesvirus and thereby preventing entry of the virus to cells.

The present invention provides a pharmaceutical composition for preventing or treating herpesvirus infections, which composition contains a substance inhibiting the binding of glycoprotein B to a non-muscle myosin heavy chain IIA or a non-muscle myosin heavy chain.

The present invention relates to a pharmaceutical composition when used for inhibiting a herpesviridae infection and/or providing relief from a herpesvindae infection in a subject. The composition includes an effective amount of an extract from a plant in the Asteraceae family.

Disclosed are: an inhibitor of herpesvirus infection; a method for the inhibition of herpesvirus infection; and a typical utilization method thereof. The inhibitor of herpesvirus infection comprises an active ingredient which can bind to glycoprotein B or a receptor for glycoprotein B and can inhibit the interaction between glycoprotein B and a receptor for glycoprotein B.

The invention relates to the technical field of biology and particularly provides equine herpesvirus 1 gB-gD fusion protein, a recombinant vector, a eukaryotic cell strain, a preparation method of therecombinant vector, and a vaccine. The equine herpesvirus 1 gB-gD fusion protein recombinant vector provided herein comprises a eukaryotic expression vector fragment and an equine herpesvirus 1 gB-gDgene fragment; the recombinant vector herein allows both equine herpesvirus 1 glycoproteins gB and gD to be expressed in an exogenous system at any time. A construction method provided herein includes: screening CHO (Chinese hamster ovary ) cells containing the recombinant vector are screened to obtain a CHO cell strain that may stably express the equine herpesvirus 1 gB-gD fusion protein; the construction method is simple, easy to perform, and suitable for successful screening of eukaryotic cell strains to stably and highly express eukaryotic equine herpesvirus 1 gB-gD fusion protein; a feasible technical scheme is provided for subsequent various researches, such as vaccine preparation and other applications.

Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. Also disclosed is a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by a mathematical equation. A new live, attenuated vaccine formulation is disclosed that is effective against neurologic disease due to equine herpesvirus-1.

The invention relates to equine herpesvirus-1 XJYM2019, protein of the virus and a vaccine based on the virus and protein thereof. The invention also relates to a DNA fragment comprising the gene of the virus and a genetic engineering vaccine based on the gene of the virus. Besides, the invention relates to an antibody reacting with the virus and a diagnostic test for detecting the virus or antibody against the virus.

Indirect ELISAs to detect exposure to Felis catus gammaherpesvirus 1 (FcaGHV1) in domestic cats. These ELISAs detect feline serum antibodies to ORF52 and ORF38 of FcaGHV1. The ELISA assays are sensitive, specific, and adaptable for scale up use in high throughput diagnostics.

We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence.

The invention discloses a safe detection kit for detecting I-type and IV-type horse herpes viruses, the safe detection kit comprises a kit body, a protection structure is arranged in the kit body, the protection structure comprises a bottom plate, the bottom plate is arranged at the bottom end in the kit body, a test tube body is arranged in a limiting hole, and the test tube body is arranged in the limiting hole. A reserved groove is formed in the top of one end of the box cover, and a marking structure is fixed to the other end of the box cover. By arranging the protection structure, when the test tube bodies are placed, the test tube bodies are taken, penetrate through preformed holes and are inserted into limiting holes, the bottoms of the test tube bodies can be limited through the limiting holes, bottle bodies of the test tube bodies can be limited through the preformed holes, and the test tube bodies cannot collide with one another; the test tube bodies can be protected through the limiting holes, shaking of the test tube bodies in the limiting holes is reduced, all the test tube bodies can be conveniently taken out of the kit body by lifting the handle upwards, and the convenience of the kit is improved.